Beta Bionics initiated with a Buy at Lake Street

Lake Street analyst Brooks O’Neil initiated coverage of Beta Bionics (BBNX) with a Buy rating and $30 price target Beta’s iLet Bionic Pancreas offers “groundbreaking simplicity for patients, caregivers, and doctors,” says the analyst, who believes Beta is in the early stages of the development of a differentiated patch pump and a first-of-its-kind bihormonal configuration of the iLet. These two projects are unlikely to reach the U.S. market before late 2027, but the firm sees “significant potential for both pumps,” the analyst added.